Glaxo shifting Tritec ulcer marketing resources to CNS, respiratory and antivirals.
Executive Summary
GLAXO SHIFTING RESOURCES FROM TRITEC TO OTHER PRODUCT AREAS, Glaxo Wellcome CEO Robert Ingram told a Bear Stearns health care conference Sept. 9 in New York City. Glaxo's expectations for Tritec (ranitidine bismuth citrate) were overly optimistic, Ingram acknowledged: "We overestimated the size of that market. It is much smaller than we had originally forecast. It's probably in the U.S. about a $100 mil. market." While Glaxo will continue to promote Tritec in targeted markets, particularly managed care, the company will "devote our real detailing and promotional support to our other growth opportunities," Ingram said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth